Karyopharm：XPORT-EC-042 III期未达到PFS终点

XPORT-EC-042 III期试验中，TP53野生型子宫内膜癌患者接受selinexor维持治疗未达到主要PFS终点。在mITT人群中观察到selinexor有数值优势（HR 0.76，p=0.0791），但未达到统计学意义。公司将在未来医学会议上公布完整数据，并表示该结果不影响其他正在进行的selinexor试验。

关键事实

申报时间: 2026年7月31日 12:30
事件: 顶线结果
方向: 消极
公司: KPTIKaryopharm
资产: selinexor
来源: SEC 8-K
可信度: 有来源
意向性治疗人群入组: 257
改良意向性治疗人群入组: 220

来源摘录

8-K false 0001503802 0001503802 2026-07-30 2026-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2026 Karyopharm Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36167 26-3931704 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 85 Wells Avenue , 2nd Floor Newton , Massachusetts 02459 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (617) 658-0600 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-

SEC 8-K